| Revenue growth | ₹540cr consolidated revenue; CRDMO segment grew 60% YoY. |
|---|---|
| Margins | EBITDA margins steady at 38%; PAT margins at 24%. |
| Demand visibility | Strong visibility for commercialized molecules and emerging modalities like ADCs. |
| Management confidence | Balanced and optimistic, emphasizing technology edge and long-term partnerships. |
Growth
Consolidated revenue reached ₹540cr, driven by a 60% surge in the CRDMO segment. Growth is primarily volume-led across commercial products.
Outlook
Investing ₹150cr to finish Units 2 and 3; Unit 4 planning underway. Target 22% historical growth rate for full year.
Risks
Business model lumpiness makes quarterly performance inconsistent. Potential U.S. tariff shifts and client concentration in late-stage molecules remain key bear-case triggers.
Earnings Call filed with NSE, NSE: ANTHEM. Summary written with AI assistance from the document.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹890.35
- Market cap
- ₹50,144 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 87.1×Sector 47.4×
- Promoter holding
- 71.42%-3.26% QoQ
- FII holding
- 2.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Other Announcement
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
- Value
- ₹82.67 Cr
Anthem Biosciences Legal & Regulatory
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
- Value
- ₹127.7 Cr
Anthem Biosciences Management Change
Anthem Biosciences appointed S.R. Batliboi & Associates LLP as Statutory Auditor and noted director changes, including a rotation and continuation of directorship.
Anthem Biosciences Annual General Meeting
Anthem Biosciences held its 20th AGM on July 22, 2026. Shareholders approved all business resolutions, including financial statements, dividend declaration, and statutory auditor appointments.
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences Results Update
Anthem Biosciences reported Q1FY27 revenue of ₹418.2 Crore and profit after tax of ₹119.9 Crore. The company continues its focus on margin improvement and cost efficiencies.